Periodic Reporting for period 1 - SPECTROPLAST (Introducing silicone to the world of additive manufacturing)
Période du rapport: 2019-03-01 au 2019-06-30
Silicone elastomeric components are traditionally produced through liquid injection moulding (LIM). Such techniques present intrinsic limitations of being long and expensive, viable only for high volume production, and also not suited for complex geometries. This causes 7% - 10% of the global silicone parts demand remaining unmet. Additive Manufacturing (AM) holds the potential to be a complementary process to fill this gap, but so far, its usage has been limited by the unsuitability of soft materials like silicone to be 3D printed. .
The objective of Spectroplast project is to commercialise our patented break-through material technology which makes silicone light-curable and hence suitable for the most widely used 3D printing technologies such as stereolithography and digital light processing.
The objective of Spectroplast project is to commercialise our patented break-through material technology which makes silicone light-curable and hence suitable for the most widely used 3D printing technologies such as stereolithography and digital light processing.
Our innovative technology is a result of 5 years of R&D work at ETH Zürich. The silicone AM platform technology has been validated by testing one of our resins on an industrial-scale 3D printer. The functionality of our 3D printed silicone products was demonstrated through printing of patient-specific artificial aortic heart valve replacements which exceed minimal device performance requirements for aortic heart valve replacements. A 3D printed silicone part for eye surgery was also validated by physicians.
During the feasibility study, we defined the technical requirements needed to improve our material system technology to increase printer output. Based on the results of the market research and customer interviews, we established the customer needs, and identified the most promising markets to target (healthcare and medical). We explored the intellectual property and regulatory landscape, and established that we have the freedom to operate. Based on these results we concluded that the Spectroplast project is viable.
During the feasibility study, we defined the technical requirements needed to improve our material system technology to increase printer output. Based on the results of the market research and customer interviews, we established the customer needs, and identified the most promising markets to target (healthcare and medical). We explored the intellectual property and regulatory landscape, and established that we have the freedom to operate. Based on these results we concluded that the Spectroplast project is viable.
Spectroplast provides cutting-edge material technology that makes any standard industrial silicone light curable, and hence suitable for commercially available AM technologies. Currently, there are no companies offering a similar solution at such development stage.
Compared to the prior state of the art LIM, Spectroplast has the following socio-economic impacts:
• Ability to produce customisable medical products to save patients’ lives or make their lives more comfortable
• Reduces lead-time by 100x and costs by 5x-10x
• Enables soft components with complex geometries
• Zero material wastage during printing
• 99% reduction in energy use leading to less CO2 emissions
Compared to the prior state of the art LIM, Spectroplast has the following socio-economic impacts:
• Ability to produce customisable medical products to save patients’ lives or make their lives more comfortable
• Reduces lead-time by 100x and costs by 5x-10x
• Enables soft components with complex geometries
• Zero material wastage during printing
• 99% reduction in energy use leading to less CO2 emissions